CUE BIOPHARMA INC (CUE)
US22978P1066 - Common Stock
Taking everything into account, CUE scores 2 out of 10 in our fundamental rating. CUE was compared to 564 industry peers in the Biotechnology industry. CUE may be in some trouble as it scores bad on both profitability and health. CUE is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year CUE has reported negative net income.
CUE had a negative operating cash flow in the past year.
CUE had negative earnings in each of the past 5 years.
CUE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CUE's Return On Assets of -110.95% is on the low side compared to the rest of the industry. CUE is outperformed by 79.32% of its industry peers.
CUE's Return On Equity of -217.20% is on the low side compared to the rest of the industry. CUE is outperformed by 70.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -110.95% | ||
| ROE | -217.2% | ||
| ROIC | N/A |
ROA(3y)-64.49%
ROA(5y)-57.94%
ROE(3y)-94.98%
ROE(5y)-81.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CUE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CUE has been increased compared to 1 year ago.
The number of shares outstanding for CUE has been increased compared to 5 years ago.
Compared to 1 year ago, CUE has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -11.12, we must say that CUE is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.12, CUE is doing worse than 78.07% of the companies in the same industry.
CUE has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.11, CUE is doing worse than 64.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.12 |
ROIC/WACCN/A
WACC11.08%
2.3 Liquidity
A Current Ratio of 2.06 indicates that CUE has no problem at all paying its short term obligations.
CUE has a worse Current ratio (2.06) than 76.65% of its industry peers.
CUE has a Quick Ratio of 2.06. This indicates that CUE is financially healthy and has no problem in meeting its short term obligations.
CUE's Quick ratio of 2.06 is on the low side compared to the rest of the industry. CUE is outperformed by 75.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 2.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 22.83% over the past year.
Looking at the last year, CUE shows a very strong growth in Revenue. The Revenue has grown by 363.46%.
Measured over the past years, CUE shows a very strong growth in Revenue. The Revenue has been growing by 36.94% on average per year.
EPS 1Y (TTM)22.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.03%
Revenue 1Y (TTM)363.46%
Revenue growth 3Y20.34%
Revenue growth 5Y36.94%
Sales Q2Q%92.33%
3.2 Future
CUE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.73% yearly.
The Revenue is expected to grow by 118.81% on average over the next years. This is a very strong growth
EPS Next Y26.9%
EPS Next 2Y21.43%
EPS Next 3Y16.51%
EPS Next 5Y25.73%
Revenue Next Year130.22%
Revenue Next 2Y44.44%
Revenue Next 3Y61.52%
Revenue Next 5Y118.81%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CUE. In the last year negative earnings were reported.
Also next year CUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CUE's earnings are expected to grow with 16.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.43%
EPS Next 3Y16.51%
5. Dividend
5.1 Amount
No dividends for CUE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CUE BIOPHARMA INC
NASDAQ:CUE (11/4/2024, 8:02:10 PM)
After market: 1.54 +0.05 (+3.36%)1.49
-0.03 (-1.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap89.71M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -110.95% | ||
| ROE | -217.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.06 | ||
| Quick Ratio | 2.06 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)22.83%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y26.9%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)363.46%
Revenue growth 3Y20.34%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y